NCT06801470View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

CD-001

CD-001 administered as an intravenous (IV) infusion.

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute&Hospital, Tianjin

All Listed Sponsors
lead

CD (Suzhou) Biopharma Co., Ltd.

OTHER